We Are Part of Biocenter Kuopio & Finland

Something that I have probably forgotten to mention is that from the beginning of 2026, we have been part of Biocenter Kuopio. And "we" means here Medicinal Chemistry & Organic Synthesis (MCOS) unit, which was accepted as a node of the Biocenter Finland's platform called Drug Discovery and Chemical Biology (DDCB) consortium (headed by Prof. Päivi Tammela, University of Helsinki). DDCB coordinates infrastructure and expertise in the areas of drug discovery and chemical biology, and makes it available to the scientific community.

So, we provide services from early-stage drug discovery, through lead optimization, to highly potent novel target-based clinical drug candidates that have fine-tuned pharmacokinetic properties, by using computational drug design, medicinal chemistry, and bioanalytical methods, together with the Drug Design & Molecular Modeling (DDMM) partnering node.

MCOS unit is also part of the roadmap for national research infrastructures in Finland (FIRI2024), which is a partner of EU-OPENSCREEN European Research Infrastructure Consortium (ERIC), which, in turn, supports academic researchers and companies aiming to utilise chemical biology tools to advance basic research or early drug discovery projects. I probably also forgot to mention about that one last year. Well, 70% of our part of the RCF-funding was cut, but let's hope we can still get some new instrument investment with that funding soon!

 

 

And the service has started nicely, we already have the first supported publication out! 🙌 Well, the biggest acknowledgement for that goes to Janne and our UPLC (not in the figure though)!